Atovaquone
- Generic Name
- Atovaquone
- Brand Names
- Malarone, Mepron
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19ClO3
- CAS Number
- 95233-18-4
- Unique Ingredient Identifier
- Y883P1Z2LT
- Background
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
- Indication
主要用于治疗恶性疟原虫感染（对氯喹敏感或耐药者）；还可用于艾滋病患者合并卡氏肺囊虫病或弓形原虫性脑炎等治疗以及轻中度不能耐受复方磺胺药的肺孢子菌肺炎（PCP肺炎）。
- Associated Conditions
- Malaria caused by Plasmodium falciparum, Pneumocystis Jirovecii Pneumonia, Toxoplasma gondii encephalitis, Acute, uncomplicated Malaria caused by plasmodium falciparum, Mild Babesiosis, Mild Pneumocystis jiroveci pneumonia, Moderate Babesiosis, Moderate Pneumocystis jiroveci pneumonia
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
- Conditions
- High-grade GliomaMedulloblastomaDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 18
- Registration Number
- NCT06624371
- Locations
- 🇺🇸
Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta: Scottish Rite, Atlanta, Georgia, United States
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
- Conditions
- Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 28
- Registration Number
- NCT05998135
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Interventions
- Drug: Standard of care chemotherapyRadiation: Standard of care radiotherapy
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 21
- Registration Number
- NCT04648033
- Locations
- 🇬🇧
Western General Hospital, NHS Lothian, Edinburgh, United Kingdom
🇬🇧Guy's and St Thomas', London, United Kingdom
🇬🇧Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom
Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT04568772
- Locations
- 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of
Safety and Efficacy of NF135 CPS Immunization
- Conditions
- Immunization; InfectionMalaria,FalciparumControlled Human Malaria Infection
- Interventions
- Biological: CPS-immunizationBiological: malaria challenge infection, P. falciparum NF54Biological: malaria challenge infection, P. falciparum NF135.C10Biological: CPS-immunization (A/L)
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT03813108
- Locations
- 🇳🇱
Radboud university medical centre, Nijmegen, Gelderland, Netherlands
Drug Combinations of Atovaquone-Proguanil (AP) With ACT
- Conditions
- Plasmodium Falciparum Malaria (Drug Resistant)
- Interventions
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
- Target Recruit Count
- 252
- Registration Number
- NCT03726593
- Locations
- 🇰🇭
Stung Treng Referral Hospital, Stung Treng, Cambodia
🇰🇭Anlong Veng Referral Hospital, Ânlóng Vêng, Cambodia
🇰🇭Kratie Referral Hospital, Kratie, Cambodia
Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT03568994
- Locations
- 🇺🇸
Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States
🇺🇸Johns Hopkins Medicine, Baltimore, Maryland, United States
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
- Conditions
- Malaria,FalciparumControlled Human Malaria InfectionTransmissionGametocytes
- Interventions
- Other: malaria challenge infection, P. falciparum 3D7Other: Blood stage malaria challenge infection, P. falciparum 3D7
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT03454048
- Locations
- 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands
Atovaquone as Tumour HypOxia Modifier
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 46
- Registration Number
- NCT02628080
- Locations
- 🇬🇧
Churchill Hospital, Oxford, Oxfordshire, United Kingdom
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
- Conditions
- Rabies
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- State University of New York - Upstate Medical University
- Target Recruit Count
- 103
- Registration Number
- NCT02564471
- Locations
- 🇺🇸
State University of New York, Upstate Medical University (SUNY-UMU), Syracuse, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.